About BennuBio
BennuBio is a Healthcare company based in Albuquerque (United States) founded in 2018. It operates as a flow cytometry equipment and services are provided for cancer research. BennuBio has raised $7.82 million across 6 funding rounds from investors including HHS, Sun Mountain Capital and Cottonwood Technology Fund. The company has 4 employees. BennuBio offers products and services including Velocyt® and Intact Spheroid Analysis. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Cell Biology. Its legal entity is BENNUBIO INC. Its competitors include Cytek Biosciences, Accuri Cytometers, ACEA Biosciences, Bioaffinity technologies and Orflo and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
BennuBio was founded in 2018 and is based in Albuquerque, United States. Operations focus on the biotechnology sector, where flow cytometry equipment and services are offered for cancer research and drug development. The Velocyt system, a 3D multicellular model, is utilized to advance these applications. Additional development efforts target rare cell sorting and 3D tissue models for disease studies.
- Headquarters Albuquerque, United States
- Employees 4
- SectorsHealthcare
- Phone•••• ••••
- Website bennubio.com
- Social LinkedIn
- Legal Name Bennubio Inc
- Total Equity Funding$7.82M (USD)
in 6 rounds
- Latest Funding Round$222.07K (USD), Grant
Mar 2023
- InvestorsHHS
& 4 more
- Employee Count4
Products & Services of BennuBio
BennuBio offers a comprehensive portfolio of products and services, including Velocyt® and Intact Spheroid Analysis.
Hardware for rapid 3D multicellular model analysis and workflow improvement.
Tool for analyzing spheroids in drug discovery processes.
Funding Insights of BennuBio
BennuBio has successfully raised a total of $7.82M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $222.07 thousand completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.82M
- Total Rounds 6
- Last Round Grant — $222,073
- First Round $1.5M
(Sep 2018)
- Investors Count 5
All 6 funding rounds of BennuBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2023 | $222,073 | Grant | – | – | |
| Mar 2022 | $1.32M | Series B | – | – | – |
| Aug 2021 | $247,435 | Grant | – | – | |
| Mar 2020 | $5M | Series B | – | Co-win Ventures | |
| Sep 2019 | $999,434 | Grant | – | – | |
| Sep 2018 | $1.5M | Series A | – | Cottonwood Technology Fund, Sun Mountain Capital | – |
5 investors in total: 5 institutional.
Investors in BennuBio
BennuBio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Sun Mountain Capital and Cottonwood Technology Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity fund focused on multiple sectors | 2006 | sunmountaincapital.com | Santa Fe, United States | |
- | – | cottonwood.vc | - | |
VC fund investing in startups | – | cowinvc.com | Suzhou, China | |
- | – | tramwayventurepartners.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for BennuBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BennuBio
9 people are tracked at BennuBio (3 in leadership, 6 in team); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Stephen McKernan | CFO | Leadership |
John O’Rourke | CEO & President | Leadership |
Steven Graves | Director of Technology | Leadership |
Benjamin Brown | Lead Production Engineer | Team |
Jason Urvanejo | Lead Project Engineer | Team |
José López | Manufacturing Production Engineer | Team |
Bruce Edwards | Data Systems Consultant | Team |
Andrew Shreve | Research & Development Consultant | Team |
James Freyer | Scientific Consultant | Team |
Complete people profiles for BennuBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BennuBio
3 dated milestones of BennuBio across 5 years, from founding to its latest funding, stage changes and deals.
- Founded BennuBio is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Grant, of $222K.
Competitors of BennuBio
BennuBio has 10 listed competitors in our database, 8 of them funded. They include Cytek Biosciences, Accuri Cytometers, ACEA Biosciences, Bioaffinity technologies and Orflo, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cytekbio.com | 2014 | San Francisco, United States | $132M | 676 | Advanced flow cytometry systems are manufactured for research applications. | |
| accuricytometers.com | 2004 | Ann Arbor, United States | $30.91M | – | Compact flow cytometers for cell analysis are developed and provided. | |
| aceabio.com | 2002 | San Diego, United States | $37.89M | 5,968 | Instruments for life science research are developed and marketed. | |
| bioaffinitytech.com | 2014 | San Antonio, United States | $9.05M | 65 | IVD platforms are developed to detect and target cancer cells. | |
| orflo.com | 2003 | Ketchum, United States | $4.36M | – | Instrumentation for cell and protein analysis is developed and marketed. | |
| nanofcm.com | 2014 | Nottingham, United Kingdom | – | 3 | Offers advanced tools for nanoparticle analysis in biotechnology and healthcare. | |
| intellicyt.com | 2006 | Albuquerque, United States | $13.82M | – | Screening solutions are provided using bead-based and cell-based assays. | |
| amphasys.com | 2012 | Lucerne, Switzerland | – | – | Developer of label-free technology for pollen viability analysis | |
| fluorofinder.com | 2008 | Westminster, United States | $4.66M | – | Design and search tool to find the best flow cytometry products for the panel | |
| cyntellect.com | 1997 | San Diego, United States | $48.6M | – | Offers technology for cell analysis, purification, and processing. |
Detailed competitors of BennuBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as BennuBio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bennubio
Complete news archive for BennuBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BennuBio
BennuBio was founded in 2018.
BennuBio is headquartered in Albuquerque, United States. It is registered at Albuquerque, New Mexico, United States.
BennuBio is a funded company, having raised a total of $7.82M across 6 funding rounds to date. The company's 1st funding round was a Series A of $1.5M, raised on Sep 2018.
BennuBio has 4 employees.
BennuBio was founded in 2018 and is based in Albuquerque, United States. Operations focus on the biotechnology sector, where flow cytometry equipment and services are offered for cancer research and drug development. The Velocyt system, a 3D multicellular model, is utilized to advance these applications. Additional development efforts target rare cell sorting and 3D tissue models for disease studies.
BennuBio's top competitors include Cytek Biosciences, Bioaffinity technologies and Accuri Cytometers.
BennuBio offers Velocyt® and Intact Spheroid Analysis.
BennuBio has 5 investors. Key investors include HHS, Sun Mountain Capital, Cottonwood Technology Fund, Co-win Ventures, and Tramway Venture Partners.
BennuBio operates through Bennubio Inc.